Please assess the completion status of the following clinical trial:

Trial Title: A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be documented to have Central Diabetes Insipidus (CDI) by at least two of the following four criteria (a-d):~  1. Failure to increase urine osmolality above 300 mOsm/kg during a period of fluid deprivation sufficient to raise plasma osmolality and sodium above the upper limit of normal level for the reference laboratory (usually 295 mOsm/kg and 148 mEq/l, respectively)~ 2. Complete and continuous control of the DI by desmopressin therapy without breakthrough diuresis, hypernatremia, hyponatremia, or symptoms or signs of water intoxication.~ 3. A deficient plasma vasopressin response to osmotic or non-osmotic stimulation.~ 4. Absence of the posterior pituitary bright spot on T-1 weighted midsagittal magnetic resonance imaging (MRI) of the brain.~* Given written informed consent prior to any trial-related procedure is performed~* 24 hour urine volume (mL), urine osmolality (mOsm/kg), urine specific gravity, and serum sodium (mEq/L) maintained at a normal level by desmopressin nasal administration~* Outpatient~* The participant is, in the investigator's opinion, otherwise healthy~* Be willing and able to comply with the protocol requirements including restriction of water intake~Exclusion Criteria:~* Presence or a history of nephrogenic diabetes insipidus or diabetes mellitus~* Presence of uncorrected hypothyroidism, hypoadrenalism or hypogonadism~* Abnormalities or disease of the oral cavity that might affect the release and absorption of drug~* Unable to be placed on water-intake restriction starting from two hours before bedtime~* Presence of a hypothalamus abnormality leading to thirst disorder~* Evidence of hepatic, renal, cardiac, or pulmonary dysfunction~* Uncontrolled hypertension~* Treatment with another investigational product within the past 3 months~* Concurrent treatment with diuretics, chlorpropamide, tricyclic antidepressants, indomethacin, carbamazepine~* Alcohol dependency or drug abuse~* Breastfeeding, pregnant, or likely to become pregnant~* A mental condition, the lack of decision-making ability, dementia or a speech handicap~* Any other reason that the Investigator believes inappropriate

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: EXPERIMENTAL): Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).